NO942551L - Humanproteaseinhibitorvariant av Kunitz-type - Google Patents

Humanproteaseinhibitorvariant av Kunitz-type

Info

Publication number
NO942551L
NO942551L NO942551A NO942551A NO942551L NO 942551 L NO942551 L NO 942551L NO 942551 A NO942551 A NO 942551A NO 942551 A NO942551 A NO 942551A NO 942551 L NO942551 L NO 942551L
Authority
NO
Norway
Prior art keywords
amino acid
protease inhibitor
variant
type human
naturally occurring
Prior art date
Application number
NO942551A
Other languages
English (en)
Norwegian (no)
Other versions
NO942551D0 (no
Inventor
Fanny Norris
Kjeld Norris
Soeren Erik Bjoern
Lars Christian Petersen
Ole Hvilsted Olsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO942551D0 publication Critical patent/NO942551D0/no
Publication of NO942551L publication Critical patent/NO942551L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Prostheses (AREA)
NO942551A 1992-01-07 1994-07-06 Humanproteaseinhibitorvariant av Kunitz-type NO942551L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK9200004 1992-01-07
PCT/DK1993/000003 WO1993014120A1 (en) 1992-01-07 1993-01-07 A human kunitz-type protease inhibitor variant

Publications (2)

Publication Number Publication Date
NO942551D0 NO942551D0 (no) 1994-07-06
NO942551L true NO942551L (no) 1994-09-07

Family

ID=8153774

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942551A NO942551L (no) 1992-01-07 1994-07-06 Humanproteaseinhibitorvariant av Kunitz-type

Country Status (15)

Country Link
EP (1) EP0621870B1 (ru)
JP (1) JPH07506241A (ru)
AT (1) ATE152735T1 (ru)
AU (1) AU675925B2 (ru)
CA (1) CA2127250A1 (ru)
CZ (1) CZ164594A3 (ru)
DE (1) DE69310499D1 (ru)
FI (1) FI943232A0 (ru)
HU (1) HUT70294A (ru)
IL (1) IL104326A0 (ru)
NO (1) NO942551L (ru)
NZ (1) NZ246568A (ru)
RU (1) RU94045952A (ru)
WO (1) WO1993014120A1 (ru)
ZA (1) ZA9397B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE529444T1 (de) 1994-01-11 2011-11-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
ATE275583T1 (de) * 1994-01-11 2004-09-15 Dyax Corp KALLIKREINHEMMENDE ßKUNITZ-DOMÄNEß-PROTEINE UND DERIVATEN DAVON
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US5795954A (en) * 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
ATE226249T1 (de) * 1994-08-05 2002-11-15 Chiron Corp Herstellung des inhibitors fuer die komplexbildung des gewebefaktors
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
CA2220497A1 (en) * 1995-05-08 1996-11-14 Scios, Inc. Kunitz type protease inhibitors
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
BR9708021A (pt) 1996-03-11 1999-07-27 Bayer Ag Proteína substancialmente purificada composição farmacêutica sequência de ácido nucleico isolada vetor de express o de protéina auto-replicante e processos para inibir a atividade de protéinas de serina tratar uma condição e preparar um medicamento de uma proteína
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
CA2488558C (en) 2002-06-07 2013-08-20 Dyax Corp. Prevention and reduction of blood loss
DK2386310T3 (en) * 2002-08-28 2019-02-25 Dyax Corp Methods of preserving organs and tissues
US6989369B2 (en) 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
WO2005021557A2 (en) 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
DK1976985T3 (da) * 2005-12-29 2013-10-21 Univ California Fremgangsmåder og præparater relateret til mutant Kunitz-domæne I af TFPI-2
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
AU2009327338B2 (en) 2008-12-19 2015-07-02 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
WO2010080833A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
CN101798346B (zh) * 2009-02-06 2013-05-29 复旦大学 一种酵母表达的长效重组人组织因子途径抑制物
SI2521568T1 (sl) 2010-01-06 2019-01-31 Dyax Corp. Proteini, ki vežejo plazemski kalikrein
NZ603028A (en) 2010-03-19 2014-11-28 Baxter Healthcare Sa Tfpi inhibitors and methods of use
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp KALLIKREIN PLASMA BINDING PROTEINS
NZ724133A (en) 2012-03-21 2020-07-31 Baxalta Inc Tfpi inhibitors and methods of use
JP7003354B2 (ja) 2015-12-11 2022-03-04 武田薬品工業株式会社 遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner

Also Published As

Publication number Publication date
CA2127250A1 (en) 1993-07-22
JPH07506241A (ja) 1995-07-13
AU675925B2 (en) 1997-02-27
DE69310499D1 (de) 1997-06-12
CZ164594A3 (en) 1994-12-15
WO1993014120A1 (en) 1993-07-22
FI943232A (fi) 1994-07-06
EP0621870B1 (en) 1997-05-07
HU9401992D0 (en) 1994-09-28
HUT70294A (en) 1995-09-28
FI943232A0 (fi) 1994-07-06
RU94045952A (ru) 1996-10-10
ZA9397B (en) 1993-08-10
IL104326A0 (en) 1993-05-13
EP0621870A1 (en) 1994-11-02
AU3345893A (en) 1993-08-03
NO942551D0 (no) 1994-07-06
ATE152735T1 (de) 1997-05-15
NZ246568A (en) 1996-02-27

Similar Documents

Publication Publication Date Title
NO942551L (no) Humanproteaseinhibitorvariant av Kunitz-type
NO942550L (no) Humanproteaseinhibitorvariant av Kunitz-type
NO942549D0 (no) Humanproteaseinhibitorvariant av Kunitz-type
MX9101788A (es) Composiciones de tinta a base de agua
MX9102407A (es) 4 arilpiperazinas y 4-arilpiperidinas novedosas.
MX9201416A (es) Peptidos y pseudopeptidos antitromboticos.
FI935172A0 (fi) Inhibitorer av katepsin G och elastas foer foerhindrande degeneration avbindvaevnad
CA2043228A1 (en) Use of magnesium-pyridoxal-5'-phosphate-glutaminate for the prevention of diseases which result from vascular lesions
EP0354820A3 (en) Novel peptide derivatives and anti-dementia agents
NO901558L (no) Vasoaktive peptider.
ITMI930724A0 (it) Peptidi ad attivita' immunomodulatoria derivati da frammenti di leucochinina
FR2700262B1 (fr) Prothèse partielle du genou.
KR940021982U (ko) 청소기용 사이클론의 압력 조절장치
KR930016980U (ko) Tv의 고압조기 방전회로
KR940021304U (ko) 고압 개폐기의 동시 투입 방지장치